Enliven Therapeutics, Inc. (ELVN) insider trading

By person

34 insiders · 414 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Orbimed Advisors LLC entity

10% owner

$25.00M (2)

$74.56M (8)

−$49.56M

6,555,102

8.95%

$252.16M

—

5AM Partners VI, LLC entity

10% owner

—

$29.80M (8)

−$29.80M

635,341

0.8671%

$24.44M

−75.5%

David P Bonita

Director

$25.00M (2)

—

+$25.00M

1,666,666

2.27%

$64.11M

—

Rishi Gupta

Director

—

$22.88M (2)

−$22.88M

7,663,349

10.46%

$294.80M

+864.0%

Ra Capital Management, L.p. entity

Former 10% owner

$14.83M (10)

—

+$14.83M

2,122,465

2.90%

$81.65M

—

Joseph P Lyssikatos

Chief Scientific Officer

—

$11.75M (60) scheduled

−$11.75M

758,938

1.04%

$29.20M

—

Mark Chin

Director

$11.00M (2)

—

+$11.00M

2,344,072

3.20%

$90.17M

—

Mika K Derynck

Director

—

$9.56M (1) scheduled

−$9.56M

0.0000%

$0.00

—

Samuel Kintz

President and CEO

—

$7.41M (51) scheduled

−$7.41M

890,392

1.22%

$34.25M

—

Helen Louise Collins

Chief Medical Officer

—

$6.11M (27) scheduled

−$6.11M

25,000

0.0341%

$961.71K

—

Anish Patel

Chief Operating Officer

—

$5.90M (45) scheduled

−$5.90M

235,011

0.3207%

$9.04M

—

New Enterprise Associates 14, L.P. entity

10% owner

$7.60M (1)

$2.27M (34)

+$5.33M

2,611,050

3.56%

$100.44M

—

Barbara Dalton

Director

$5.00M (1)

—

+$5.00M

1,557,722

2.13%

$59.92M

—

Pfizer Inc entity

10% owner

$5.00M (1)

—

+$5.00M

1,557,722

2.13%

$59.92M

—

Benjamin Hohl

Chief Financial Officer

—

$4.74M (68) scheduled

−$4.74M

38,000

0.0519%

$1.46M

—

Braden Michael Leonard

10% owner

$964.52K (7)

$5.36M (6)

−$4.40M

1,997,774

2.73%

$76.85M

−23.7%

Rock Springs Capital Management LP entity

10% owner

$4.00M (1)

—

+$4.00M

523,411

0.7144%

$20.13M

—

Mette Kirstine Agger

Director

$3.00M (1)

—

+$3.00M

1,432,722

1.96%

$55.11M

—

Arix Bioscience plc entity

10% owner

$3.00M (1)

—

+$3.00M

1,554,558

2.12%

$59.80M

—

Invest A/S Lundbeckfond

10% owner

$3.00M (1)

—

+$3.00M

1,432,722

1.96%

$55.11M

—

Rahul D. Ballal

Director

—

$2.56M (12) scheduled

−$2.56M

22,341

0.0305%

$859.42K

—

Richard A. Heyman

Director

—

$1.09M (33) scheduled

−$1.09M

146,320

0.1997%

$5.63M

—

Lori Anne Kunkel

Director

—

$850.25K (5) scheduled

−$850.25K

52,925

0.0722%

$2.04M

+15.2%

J. Scott Garland

Director

—

$606.72K (1) scheduled

−$606.72K

0.0000%

$0.00

—

David M Mott

Director

$313.59K (9)

—

+$313.59K

229,224

0.3128%

$8.82M

—

Commodore Capital LP entity

10% owner

$177.22K (3)

—

+$177.22K

1,448,640

1.98%

$55.73M

+111.1%

Michael Gray

CFO & COO

—

$91.37K (3)

−$91.37K

27,610

0.0377%

$1.06M

+1,513%

Andrew J. Schwab

Director

—

960,383

1.31%

$36.94M

—

Carl Goldfischer

Director

—

703,380

0.9600%

$27.06M

—

Bay City Capital LLC entity

10% owner

—

703,380

0.9600%

$27.06M

—

Lundbeck A S H

10% owner

—

522,499

0.7131%

$20.10M

+17.9%

Alexandria Venture Investments, LLC entity

10% owner

—

293,013

0.3999%

$11.27M

—

Jake Bauer

Director

—

87,372

0.1192%

$3.36M

—

Kenneth Attie

SVP, CMO

—

34,100

0.0465%

$1.31M

—

Enliven Therapeutics, Inc.

What the insiders did Net selling

By person